2-Cyclohexyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane>97.0%(GC)(T)1g

2-[5-(Benzyloxy)pentyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 98%, 250mg

(R)-2-((4-Nitrophenethyl)amino)-1-phenylethanol hydrochloride, 95.0%, 10g

2-(TERT-BUTYLCARBONYLAMINO)PHENYLBORONIC ACID PINACOL ESTER, 95%, 1g

N-BOC-3-(4-BROMOPHENYL)AZETIDINE, 95.0%, 1g

Methyl 6-(trifluoromethyl)nicotinyl acetate, 95.0%, 250mg

N-(tert-Butyl)-2-chloro-6-methylisonicotinamide, 98%, 250mg

Methyl 2-amino-3,5-dibromo-4-methoxybenzoate, 97%, 1g

E-Plan phase EPLPHi 10x/0.25 infinity corrected IOS objective. Working distance 5.95 mm

2,2'-Bis((S)-4-phenyl-4,5-dihydrooxazol-2-yl)-1,1'-biphenyl, 250mg

4-Fluorobenzo[b]thiophene, 95.0%, 1g

3,4-Difluoro-3',4'-dimethoxybenzophenone, 97.0%, 1g

2-(Cyclopentyloxy)acetic acid, 95.0%, 10g